- Home
- BFST vs CGEM Comparison
BFST vs CGEM Comparison
Compare BFST & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BFST
- CGEM
- Stock Information
- Founded
- BFST 2006
- CGEM 2016
- Country
- BFST United States
- CGEM United States
- Employees
- BFST N/A
- CGEM N/A
- Industry
- BFST Major Banks
- CGEM Biotechnology: Pharmaceutical Preparations
- Sector
- BFST Finance
- CGEM Health Care
- Exchange
- BFST Nasdaq
- CGEM Nasdaq
- Market Cap
- BFST 838.4M
- CGEM 730.2M
- IPO Year
- BFST 2018
- CGEM 2021
- Fundamental
- Price
- BFST $25.94
- CGEM $11.63
- Analyst Decision
- BFST Buy
- CGEM Strong Buy
- Analyst Count
- BFST 2
- CGEM 7
- Target Price
- BFST $28.00
- CGEM $31.67
- AVG Volume (30 Days)
- BFST 130.2K
- CGEM 533.4K
- Earning Date
- BFST 01-21-2025
- CGEM 11-07-2024
- Dividend Yield
- BFST 2.16%
- CGEM N/A
- EPS Growth
- BFST N/A
- CGEM N/A
- EPS
- BFST 2.32
- CGEM N/A
- Revenue
- BFST $249,883,000.00
- CGEM N/A
- Revenue This Year
- BFST N/A
- CGEM N/A
- Revenue Next Year
- BFST $18.42
- CGEM N/A
- P/E Ratio
- BFST $11.18
- CGEM N/A
- Revenue Growth
- BFST 1.14
- CGEM N/A
- 52 Week Low
- BFST $18.97
- CGEM $9.24
- 52 Week High
- BFST $30.30
- CGEM $30.19
- Technical
- Relative Strength Index (RSI)
- BFST 35.06
- CGEM 37.71
- Support Level
- BFST $25.36
- CGEM $10.44
- Resistance Level
- BFST $29.03
- CGEM $12.79
- Average True Range (ATR)
- BFST 0.79
- CGEM 0.68
- MACD
- BFST -0.38
- CGEM -0.03
- Stochastic Oscillator
- BFST 15.67
- CGEM 35.53
About BFST Business First Bancshares Inc.
Business First Bancshares Inc is a United States-based bank holding company. The company's services include personal and commercial banking, treasury management, and wealth solutions. It provides a range of financial services to small-to-midsized businesses and professionals. The company generates majority of its revenues from interest income on loans, customer service and loan fees, and interest income from securities.
About CGEM Cullinan Oncology Inc.
Cullinan Therapeutics Inc is a biopharmaceutical company. It has diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, create differentiated ideas, identify the appropriate targets, and select the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications.